A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction.

Trial Profile

A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs Sacubitril/valsartan (Primary) ; Enalapril
  • Indications Chronic heart failure
  • Focus Therapeutic Use
  • Acronyms PARALLEL-HF
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 18 Aug 2017 Planned End Date changed from 24 Nov 2018 to 26 Nov 2018.
    • 10 Jun 2017 Biomarkers information updated
    • 17 Jan 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top